Eduardo Diaz-Rubio
Overview
Explore the profile of Eduardo Diaz-Rubio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
5198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg J, et al.
Eur J Cancer
. 2024 Jun;
207:114160.
PMID: 38896997
Background: The liver is the most frequent site of metastases in colorectal cancer (CRC). This study aimed to assess the response rate and survival outcomes in metastatic CRC patients with...
2.
Ou F, Ahn D, Dixon J, Grothey A, Lou Y, Kasi P, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627145
Patients And Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each...
3.
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al.
J Clin Oncol
. 2023 Jul;
41(21):3663-3669.
PMID: 37459755
Purpose: To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic...
4.
Raimondi A, Nichetti F, Stahler A, Wasan H, Aranda E, Randon G, et al.
Eur J Cancer
. 2023 Jul;
190:112945.
PMID: 37441940
Background: Anti-EGFR antibodies plus doublet chemotherapy is the standard of care in RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No phase-3 level of evidence is available to guide treatment de-escalation after...
5.
Marquina G, Manzano A, Benavente C, Macias N, Rivas A, Diaz-Rubio E, et al.
Cancer Diagn Progn
. 2023 May;
3(3):302-310.
PMID: 37168968
Background/aim: In patients with advanced platinum-resistant ovarian cancer we prospectively evaluated whether trabectedin could resensitize the tumor cells to platinum rechallenge. Patients And Methods: Upon progression to platinum-based chemotherapy, trabectedin...
6.
Paz-Cabezas M, Calvo-Lopez T, Romera-Lopez A, Tabas-Madrid D, Ogando J, Fernandez-Acenero M, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358609
Colorectal cancer consensus molecular subtypes (CMSs) are widely accepted and constitutes the basis for patient stratification to improve clinical practice. We aimed to find whether miRNAs could reproduce molecular subtypes,...
7.
Calvo-Lopez T, Paz-Cabezas M, Llovet P, Ibanez M, Sastre J, Alonso-Orduna V, et al.
Cancer Biomark
. 2021 Dec;
34(2):201-210.
PMID: 34958006
Background: MicroRNAs (miRs) are frequently altered in colorectal cancer (CRC) and can be used as prognostic factors. Objective: To confirm in stage III CRC patients a reported miR signature that...
8.
Benavides M, Gomez-Espana A, Garcia-Alfonso P, Gonzalez C, Vieitez J, Rivera F, et al.
Eur J Surg Oncol
. 2021 Dec;
48(5):1123-1132.
PMID: 34872775
Introduction: Retrospective studies and meta-analyses suggest that upfront primary tumour resection (UPTR) confers a survival benefit in patients with asymptomatic unresectable metastatic colorectal cancer (mCRC) undergoing chemotherapy, however a consensus...
9.
Camps C, Lopez R, Anton A, Aranda E, Carrato A, Cruz J, et al.
JCO Oncol Pract
. 2021 Feb;
17(8):e1162-e1169.
PMID: 33621121
Purpose: Measuring and tracking quality of care is highly relevant in today's health care. The Quality Oncology Practice Initiative (QOPI) program is a referral for evaluating oncology practices worldwide. Excellence...
10.
Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, et al.
Drugs Aging
. 2021 Feb;
38(3):219-231.
PMID: 33615402
Background: Biologicals, in combination with chemotherapy, are recommended as first-line treatment of metastatic colorectal cancer (mCRC); however, evidence guiding the appropriate management of older patients with mCRC is limited. Objective:...